Private company
Chiasma (United States)
Chiasma (United States) is an American pharmaceutical preparations company based in Waltham, founded in 2001.1
Last updated Oct 20, 2026.
Overview
What it owns
What Chiasma (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.0M4 Dec 31, 2020 | $654.0K4 Dec 31, 2019 | +56.9% |
| Accumulated depreciation | $492.0K4 Dec 31, 2020 | $320.0K4 Dec 31, 2019 | +53.8% |
| Property and equipment, net | $534.0K4 Dec 31, 2020 | $334.0K4 Dec 31, 2019 | +59.9% |
| Operating-lease assets (leased space) | $985.0K4 Dec 31, 2020 | $1.4M4 Dec 31, 2019 | −28.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $15.5M4 Dec 31, 2020 | $27.9M4 Dec 31, 2019 | −44.5% |
| Debt securities available for sale | $151.4M4 Dec 31, 2020 | $89.5M4 Dec 31, 2019 | +69.0% |
Inventory
Leadership
Who has led Chiasma (United States), and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- Chief executive officerRaj Kannan Jun 17, 2019 to Aug 5, 20215
- Chief executive officerMark Leuchtenberger Feb 12, 2016 to Feb 12, 20166
- Chief executive officerMark J. Fitzpatrick Oct 25, 2016 to Feb 15, 20197
- PresidentRaj Kannan Feb 11, 2021 to Aug 5, 20218
- PresidentMark Leuchtenberger Feb 12, 2016 to Feb 12, 20166
- PresidentMark J. Fitzpatrick Oct 25, 2016 to Dec 7, 20207
- Chief financial officerJohn Brendan Doyle Jan 20, 2021 to Aug 5, 20219
- Chief financial officerMark J. Fitzpatrick Feb 12, 2016 to Feb 12, 201610
Board members and other officers (22)
- OfficerWilliam Ludlam Apr 2, 2018 to Aug 5, 202111
- VP, Fin & Admin., PAODrew Enamait Nov 10, 2016 to Aug 5, 202112
- OfficerChaime Orlev Jul 15, 2015 to Jul 15, 201513
- OfficerMark J. Fitzpatrick Jul 15, 2015 to Jul 15, 201514
- OfficerMark Leuchtenberger Jul 15, 2015 to Jul 15, 201515
- Chief Development OfficerRoni Mamluk Jul 15, 2015 to Dec 16, 201616
- Chief Commercial OfficerAnand Varadan Aug 19, 2015 to Aug 5, 202117
- Board memberRaj Kannan Jun 17, 2019 to Aug 5, 20215
- Board memberRoni Mamluk Jun 19, 2017 to Aug 5, 202118
- Board memberMark J. Fitzpatrick Oct 25, 2016 to Feb 15, 20197
- Board memberAnsbert Gadicke Jul 15, 2015 to Jun 13, 201619
- Board memberBard Geesaman Jul 15, 2015 to Aug 5, 202120
- Board memberBrandwein Dror Jul 15, 2015 to Jul 15, 201521
- Board memberDavid M. Stack Jul 15, 2015 to Aug 5, 202122
- Board memberJohn A. Scarlett Jul 15, 2015 to Aug 5, 202123
- Board memberMark Leuchtenberger Jul 15, 2015 to Feb 12, 201615
- Board memberScott Minick Jul 15, 2015 to Aug 5, 202124
- Board memberVincent J. Miles Jul 16, 2015 to Mar 9, 201625
- Board memberJames R. Tobin Dec 2, 2015 to Jun 13, 201626
- Board memberJohn F. Thero Dec 2, 2015 to Aug 5, 202127
- General counselLee Giguere Dec 12, 2019 to Aug 5, 202128
- General counselTara McCarthy Jan 4, 2016 to Feb 1, 201629
Former names
- CHIASMA INCSep 21, 2005 to Jul 1, 20113
Timeline
Filings
1 filings to the SEC since October 2021: 1 large holders. The latest 1:
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
1 such filings since October 2021:
- Feb 15, 2022SC 13G/A
SEC filer profile
How Chiasma (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCHIASMA, INC2
- CIK0001339469
- Filer statusNon-accelerated filer<br>smaller reporting company2
- Incorporated inDelaware2
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- Business address140 Kendrick Street, Building C East, Needham, MA 024942
- Phone617-928-53002
- Shares outstanding57,894,177 as of Apr 30, 202130
- Public float$195.2M as of Jun 30, 20204
- On EDGAR sinceSep 21, 20052
- Filings370 in all: 4 (108), 8-K (68), SC 13G/A (30), 3 (27), 10-Q (18), SC 13G (18), 425 (14), 424B5 (8)2
All 37 form types
DEFA14A (8), CORRESP (7), 10-K (6), D (6), DEF 14A (6), S-8 (5), S-8 POS (5), D/A (4), EFFECT (4), REGDEX (4), 3/A (2), 4/A (2), DRSLTR (2), S-3 (2), UPLOAD (2), 15-12B (1), 25-NSE (1), 424B4 (1), 5 (1), 8-A12B (1), CERTNAS (1), DEFM14A (1), DRS (1), DRS/A (1), POS AM (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3/A (1)
- Latest filingsAnnual report (10-K) Mar 4, 2021
Quarterly report (10-Q) May 5, 2021
Proxy statement (DEF 14A) Apr 26, 2021
Latest 8-K (8-K) Aug 5, 2021
Links
- Websitewww.chiasmapharma.com1
- WikidataQ43896128
- SEC EDGARCIK 1339469
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARRaj Kannan, Chief executive officer
- 6
- 7
- 8SEC EDGARRaj Kannan, President
- 9
- 10
- 11SEC EDGARWilliam Ludlam, Officer
- 12SEC EDGARDrew Enamait, VP, Fin & Admin., PAO
- 13SEC EDGARChaime Orlev, Officer
- 14SEC EDGARMark J. Fitzpatrick, Officer
- 15SEC EDGARMark Leuchtenberger, Officer
- 16
- 17
- 18SEC EDGARRoni Mamluk, Board member
- 19SEC EDGARAnsbert Gadicke, Board member
- 20SEC EDGARBard Geesaman, Board member
- 21SEC EDGARBrandwein Dror, Board member
- 22SEC EDGARDavid M. Stack, Board member
- 23SEC EDGARJohn A. Scarlett, Board member
- 24SEC EDGARScott Minick, Board member
- 25SEC EDGARVincent J. Miles, Board member
- 26SEC EDGARJames R. Tobin, Board member
- 27SEC EDGARJohn F. Thero, Board member
- 28SEC EDGARLee Giguere, General counsel
- 29SEC EDGARTara McCarthy, General counsel
- 30